Diego Santoro
About Diego Santoro
Diego Santoro serves as the General Manager for the Intercontinental Region at Kite, a Gilead Company, bringing extensive experience in the pharmaceuticals industry, particularly in oncology and business development.
Work at Kite Pharma
Diego Santoro serves as the General Manager for the Intercontinental Region at Kite, a Gilead Company. He has held this position since 2021 and is based in São Paulo, Brazil. In this role, he oversees operations and strategic initiatives across multiple countries, focusing on advancing Kite's mission in the field of oncology.
Education and Expertise
Diego Santoro earned a Master of Science degree in Pharmaceutical Technology from the University of Sao Paulo, where he studied from 2003 to 2005. His education includes a focus on emulsified systems, topical products, and drug development. He also holds a degree in Pharmacy from Universidade de Mogi das Cruzes, where he studied pharmaceutical technology, pharmacology, and cosmetic development from 1997 to 2000.
Background in Pharmaceuticals
Diego Santoro has extensive experience in the pharmaceuticals industry, having worked in various roles at prominent companies. He was the Oncology and Rare Diseases Business Franchise Head at Novartis Oncology from 2017 to 2021. Prior to that, he held several positions at Sandoz, including Marketing and Business Development Director and Regional Portfolio Director for Latin America.
Professional Experience at Sandoz
At Sandoz, Diego Santoro held multiple leadership roles, including Strategic Planning and Portfolio Management Director and Specialties BU Director. His tenure at Sandoz spanned from 2011 to 2017, during which he contributed to marketing strategies and business development efforts in the Latin American market.
Experience at GlaxoSmithKline
Diego Santoro worked at GlaxoSmithKline as Director of Portfolio Planning and Management from 2009 to 2011. In this role, he was responsible for overseeing product portfolios and strategic planning, further enhancing his expertise in the pharmaceutical sector.